Koninklijke Philips (NYSE:PHG) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Koninklijke Philips (NYSE:PHG - Free Report) from a hold rating to a buy rating in a research note issued to investors on Saturday.

Separately, Sanford C. Bernstein upgraded shares of Koninklijke Philips from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, March 18th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy".

Koninklijke Philips Price Performance

Shares of NYSE:PHG traded up $0.10 during trading on Friday, reaching $24.14. The company had a trading volume of 433,095 shares, compared to its average volume of 907,468. The firm's fifty day moving average is $23.56 and its 200 day moving average is $24.95. The firm has a market capitalization of $23.25 billion, a PE ratio of 56.15, a price-to-earnings-growth ratio of 0.68 and a beta of 0.76. Koninklijke Philips has a twelve month low of $20.61 and a twelve month high of $31.57. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.79 and a current ratio of 1.28.

Koninklijke Philips (NYSE:PHG - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The technology company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.14 by $0.13. The business had revenue of $4.31 billion during the quarter, compared to the consensus estimate of $4.10 billion. Koninklijke Philips had a net margin of 2.11% and a return on equity of 10.97%. The firm's quarterly revenue was down 1.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.21 EPS. On average, equities analysts forecast that Koninklijke Philips will post 1.63 EPS for the current year.

Institutional Investors Weigh In On Koninklijke Philips

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ballentine Partners LLC boosted its stake in Koninklijke Philips by 138.2% during the 2nd quarter. Ballentine Partners LLC now owns 19,847 shares of the technology company's stock worth $476,000 after acquiring an additional 11,515 shares during the last quarter. Harrington Investments INC lifted its stake in Koninklijke Philips by 3.9% in the second quarter. Harrington Investments INC now owns 25,270 shares of the technology company's stock valued at $606,000 after buying an additional 945 shares in the last quarter. U.S. Capital Wealth Advisors LLC bought a new position in Koninklijke Philips in the second quarter valued at approximately $206,000. Mitchell & Pahl Private Wealth LLC lifted its stake in Koninklijke Philips by 5.6% in the second quarter. Mitchell & Pahl Private Wealth LLC now owns 36,935 shares of the technology company's stock valued at $886,000 after buying an additional 1,957 shares in the last quarter. Finally, Perpetual Ltd lifted its stake in Koninklijke Philips by 2.6% in the second quarter. Perpetual Ltd now owns 872,646 shares of the technology company's stock valued at $20,926,000 after buying an additional 21,898 shares in the last quarter. Institutional investors and hedge funds own 13.67% of the company's stock.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.